Bins, Sander http://orcid.org/0000-0002-8280-9836
Huitema, Alwin D. R.
Laven, Pim
Bouazzaoui, Samira el
Yu, Huixin
van Erp, Nielka
van Herpen, Carla
Hamberg, Paul
Gelderblom, Hans
Steeghs, Neeltje
Sleijfer, Stefan
van Schaik, Ron H. N.
Mathijssen, Ron H. J.
Koolen, Stijn L. W.
Article History
First Online: 27 October 2018
Compliance with Ethical Standards
:
: No sources of funding were received for the preparation of this article.
: Huixin Yu is currently employed by Novartis. All her contributions to this article were made before that employment. Nielka van Erp received grants from Astellas, Janssen-Cilag BV, Novartis, GSK, Boehringer-Ingelheim, Ipsen, Roche, Pfizer, Gilead, and Sanofi and payment for lectures by Novartis, Bayer, and Sanofi. Ron H.J. Mathijssen received grants and payment for lectures by Novartis. Stijn L.W. Koolen received payment for lectures by Novartis. Sander Bins, Alwin D.R. Huitema, Pim Laven, Samira el Bouazzaoui, Carla van Herpen, Paul Hamberg, Hans Gelderblom, Neeltje Steeghs, Stefan Sleijfer, and Ron H.N. van Schaik have no conflicts of interest that are directly relevant to the contents of this article.